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A B S T R A C T
Clinical features of myelodysplastic syndromes (MDS) could be inﬂuenced by many factors, such as disease
intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment),
and ethnicity. Several previous studies have suggested such diﬀerences between Asian and European/USA
countries. In this study, to elucidate potential diﬀerences in primary untreated MDS between Japanese (JPN) and
Caucasians (CAUC), we analyzed the data from a large international database collected by the International
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Karyotype Working Group for Prognosis of MDS (300 and 5838 patients, respectively). JPN MDS were signiﬁcantly younger
with more severe cytopenias, and cytogenetic diﬀerences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7),
-9/del(9q), del(16q), and del(20q). Although diﬀerences in time to acute myeloid leukemia transformation did
not occur, a signiﬁcantly better survival in JPN was demonstrated, even after the adjustment for age and FAB
subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias,
blast percentage, cytogenetic risk) had diﬀerent impact on survival and time to transformation to leukemia
between the two groups. Although possible confounding events (e.g., environment, diet, and access to care)
could not be excluded, our results indicated the existence of clinically relevant ethnic diﬀerences regarding
survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP
patients underlines that its common risk model is adequate for CAUC and JP.
1. Introduction
Patients with myelodysplastic syndromes (MDS) show hetero-
geneous clinical features with variation in ineﬀective hematopoiesis,
morphological dysplasia, and progression to acute myeloid leukemia
(AML) [1]. MDS arises from abnormal hematopoietic stem cells, with
detectable somatic mutations in virtually all patients [2,3], and recent
studies also showed that germline mutations are found in a portion of
MDS [4,5]. These results clearly demonstrate that the genomic status is
highly inﬂuential on clinical features of MDS [3]. For example, SF3B1
mutations and the presence of ring sideroblasts are strongly associated
in MDS [6,7]. In some hematological neoplasms, incidences are related
to ethnic diﬀerences. Chronic lymphocytic leukemia is more frequent in
Caucasians (CAUC) than Japanese (JPN) [8,9] and could be attribu-
table, at least in part, to susceptibility loci of the genome [10]. MDS
appears to be more common in Non-Hispanic compared with Hispanic
people [11]. These reports support the idea that genetic background
aﬀects the incidence of some hematological neoplasms, including MDS.
Considering the importance of potential genetic diﬀerences in MDS,
ethnic backgrounds could contribute not only to the diﬀering incidence
but also could aﬀect the clinical courses of this group of disorders.
Several reports from Asian countries suggested diﬀerences in clinical
features of MDS in diﬀerent parts of the world [12–15].
The treatment strategy for MDS is usually based on clinical features,
patient-related factors, the biology of the MDS, and prognostic scoring
systems including the International Prognostic Scoring System (IPSS)
[16], and the revised IPSS (IPSS-R) [17]. The IPSS-R was developed
using data from more than 7000 MDS patients, including CAUC and
JPN. These two systems have been widely utilized and validated to
predict overall survival (OS) and risk of AML transformation by many
groups for ethnically diﬀerent populations [18–23]. In this study, we
analyzed this large International Working Group for Prognosis of MDS
(IWG-PM) database, which generated the IPSS-R, to address the ques-
tion of whether ethnic or other diﬀerences between JPN and CAUC
MDS patients inﬂuenced their clinical features and outcomes. In con-
trast to previous reports, we compared clinical factors in more detail,
with particular focus on cytogenetic abnormalities and clinical out-
comes.
2. Patients and methods
2.1. Patients
The IWG-PM collected more than 7000 primary untreated MDS
patients who had maintained clinical stability for at least 2 months, as
in the original IPSS-R study [17], under the aegis of the MDS Founda-
tion, Inc. We used both FAB [24] and WHO [25] classiﬁcation in this
study, because both were used in the original IPSS-R analysis. Patients
were self-declared as White / Caucasian (CAUC) or Japanese (JPN). It is
understood that the term Caucasian is inexact [26] but herein refers to
those White non-Hispanic or Latino individuals of US or European de-
rivation. CAUC patients came from US and EU centers; all JPN came
from Japanese centers. There were 13 major centers (including more
than 70 co-operating hospitals) contributed for CAUC patients’ data,
and 4 centers for JPN patients. In terms of JPN data, two data sets were
from center hospitals (university academic hospitals), and other two
were submitted from several hospitals (the number of hospitals were
not clear after anonymization). We evaluated only patients whose
ethnicity was indicated in the database (350 patients for JPN, and 6025
for CAUC), and then we further selected these cases by age. JPN MDS
patients were signiﬁcantly younger than CAUC patients, with median
ages of 62 years (range 16–90) and 71 years (16–106), respectively
(P < 0.001). Since patients of less than 40 years old comprised 14.3%
of the JPN group compared to 3.1% of CAUC, to aid comparability, we
restricted our analysis to patients older than 39 years in this study.
Thus, the ﬁnal number of JPN and CAUC patients for the analysis was
300 and 5838, respectively (6138 in total). For JPN, data were con-
tributed by 4 sites (two from university hospitals, and two were col-
lected from several hospitals); within the CAUC data came from 13
centers. The median year of diagnosis for these patients was 2001
(range 1964 to 2010). These sites obtained data in accordance with
their respective institutional review board approvals.
2.2. Statistical methods
As a measure of prognostic power, the Dxy coeﬃcient together with
its 95% conﬁdence interval for censored data [27] was used. Dxy is a
concordance coeﬃcient varying between -1 and 1, with 0 representing
no predictive power and 1 perfect concordance of ascribed risk and
survival and time to transformation, respectively. Adjusted curves for
survival and time to AML were calculated by weighting the comparison
subsample according to the distribution of the reference sample and
tested by a related Cox model.
Depending on the concerned variables, p-values were taken from
the Wilcoxon-Mann-Whitney-U-Test, Kendall's tau, the chi-square-test,
or the logrank-Mantel-Cox-test. Two-sided P values less than 0.05 were
considered signiﬁcant. In line with the essentially exploratory nature of
the project, no adjustment for multiple testing was applied. All analyses
were performed using the open source software R version 3.2.3 [28]
including the package "survival" [29].
3. Results
3.1. Background of the data selection
Table 1 shows the demographic details of the 40 years and over JPN
and CAUC patient cohorts within the IWG-PM database analyzed in this
study. In these cohorts, median age of JPN and CAUC patients was 65.5
and 71 years, and JPN patients were signiﬁcantly younger (Table 1,
P < 0.001). There was no diﬀerence in the distribution of gender.
3.2. FAB and WHO subtype
A signiﬁcant diﬀerence in the distribution of FAB subgroups [24]
(6136 cases) was noted between JPN and CAUC (P < 0.001, Table 1).
In the JPN group, the frequency of the following FAB subtypes was
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lower than CAUC: refractory anemia with ring sideroblasts (RARS,
6.0% for JPN, and 18.5% for CAUC), and CMML (4.7% for JPN, and
10.1% for CAUC). In terms of WHO morphologic subtypes [25] (4686
cases), the distribution was also signiﬁcantly diﬀerent (P < 0.001,
Table 1) with more refractory cytopenia with multilineage dysplasia
(RCMD) in the JPN group (41.2% and 27.9% for JPN and CAUC, re-
spectively), and less RARS (4.0% and 12.6%, for JPN and CAUC, re-
spectively) and 5q- syndrome (1.3% and 4.7% for JPN and CAUC, re-
spectively).
Table 1
Demographics of JPN and CAUC MDS in this study.
JPN CAUC P value (U-Test)
n (%) n (%)
Age n= 300 n=5838 < 0.001
median age 65.5 71
Sex n= 300 n=5838 0.5391
male 180 (60) 3606 (61.77)
female 120 (40) 2232 (38.23)
ECOG PS n=59 n=2192 0.0249
0 7 (11.86) 706 (32.21)
1 48 (81.36) 1241 (56.61)
2-4 4 (6.78) 245 (11.18)
FAB classiﬁcation n= 300 n=5836 < 0.001
RA 187 (62.3) 2280 (39.1)
RARS 18 (6.0) 1082 (18.5)
RAEB 66 (22.0) 1477 (25.3)
RAEB-T 15 (5.0) 328 (5.6)
CMML 14 (4.7) 590 (10.1)
Others 0 79 (1.4)
WHO classiﬁcation n= 226 n=4460 < 0.001
RCUD 38 (16.8) 724 (16.2)
RARS 9 (4.0) 560 (12.6)
RCMD 93 (41.2) 1243 (27.9)
RAEB-1 24 (10.6) 788 (17.7)
RAEB-2 48 (21.2) 832 (18.7)
5q- 3 (1.3) 210 (4.7)
MDS-U 0 103 (2.3)
Others 11(4.9) 0
Hb n=300 n=5836 < 0.001
median 85 99
range 38-171 23-189
PLT n=300 n=5838 < 0.001
median 75 130
range 1-1110 0-1540
WBC n=253 n=5580 < 0.001
median 3.1 4
range 0.6-12.5 0.4-12.0
ANC n=300 n=5838 < 0.001
median 1.3 1.91
range 0.12-8.0 0-10.6
PB blast (%) n= 178 n=4105 0.003
median 0 0
range 0-7 0-19
blast< 1% 93.3 84.1
BM blast (%) n= 300 n=5838 0.015
median 2 3
range 0-28 0-30
Serum ferritin n= 138 n=2502 < 0.001
median 216 342
range 5-4370 0-10000
Serum LD n=225 n=3768 0.089
elevated over normal range 69 (30.7) 963 (25.6)
RBC transion dependency n= 177 n=2498 0.038
No 132 (74.6) 1555 (67)
Yes 45 (25.4) 766 (33)
Cytogenetic risk category n= 300 n=5838 0.332
very good 3 (1) 210 (3.6)
good 214 (71.3) 4216 (72.2)
intermediate 51 (17) 774 (13.3)
poor 13 (4.3) 238 (4.1)
very poor 19 (6.3) 400 (6.9)
Clinical risk category
< IPSS-R> n=300 n=5838 < 0.001
very low 30 (10) 1136 (19.5)
low 95 (31.7) 2202 (37.7)
int 96 (32) 1123 (19.2)
high 40 (13.3) 766 (13.1)
very high 39 (13) 611 (10.5)
< IPSS> n=300 n=5832 < 0.001
Low 60 (20) 2246 (38.5)
Intermediate-1 177 (59) 2224 (38.1)
Intermediate-2 40 (13.3) 954 (16.4)
High 23 (7.7) 408 (7)
ECOG PS, European clinical oncology group performance status; FAB, French-
American-British;
RA, refractory anemia; RARS, RA with ring sideroblasts; RAEB, RA with excess
blasts;
RAEB-T, RAEB in transformation; CMML, chronic myelomonocytic leukemia;
RCUD, refractory cytopenia with unilineage dysplasia; RCMD, RC with multi-
lineage dysplasia;
5q-, 5q- syndrome; MDS-U, MDS unclassiﬁable; PB, peripheral blood; BM, bone
marrow;
IPSS, international prognostic scoring system; IPSS-R, revised IPSS.
Table 2







Karyotype N=261 (100) N=4844 (100)
+1/+1q 5 (1.9) 35(0.7) 0.033
−1/del(1p) 6 (2.3) 27 (0.6) < 0.001
der(1;7) 5 (1.9) 14 (0.3) < 0.001
−9/del(9q) 6 (2.3) 31 (0.6) 0.002
del(16q) 4 (1.5) 10 (0.2) < 0.001
del(20q) 18 (6.9) 135 (2.8) < 0.001
-Y 3 (1.1) 164 (3.4) 0.048
del(5q) 5 (1.9) 415 (8.6) < 0.001
inv(3)/t(3q)/del(3q) 2 (0.8) 17 (0.4) 0.283
t(5q) 0 16 (0.3) 0.353
t(7q) 0 10 (0.2) 0.463
−7 3 (1.1) 132 (2.7) 0.122
del(7q) 7 (2.7) 74 (1.5) 0.146
+8 10 (3.8) 280 (5.8) 0.185
+11 0 15 (0.3) 0.368
del(11q) 3 (1.1) 60 (1.2) 0.899
t(11q23) 0 7 (0.1) 0.539
del(12p) 3 (1.1) 61 (1.3) 0.877
+13 1 (0.4) 9 (0.2) 0.483
−13/del(13q) 2 (0.8) 40 (0.8) 0.918
del(17p) 3 (1.1) 28 (0.6) 0.247
i(17q) 2 (0.8) 14 (0.3) 0.179
+19 0 23 (0.5) 0.265
+21 0 42 (0.9) 0.131
−21/del(21q) 1 (0.4) 18 (0.4) 0.976
-X 0 16 (0.3) 0.353
marker chromosome 4 (1.5) 92 (1.9) 0.671
t(5q), some aberrations involving 5q; t(7q), some aberrations involving 7q.
t(11q23), translocations involving 11q23.
Table 3
Distribution of patients in age-adjusted IPSS-R category.
JPN CAUC
IPSS-RAa category n (%) n (%) P=0.010
Very Low 38 (12.7) 1051 (18)
Low 93 (31) 1959 (33.6)
Intermediate 83 (27.7) 1313 (22.5)
High 46 (15.3) 826 (14.1)
Very High 40 (13.3) 689 (11.8)
total 300 (100) 5838 (100)
a IPSS-RA, age-adjusted IPSS-R.
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3.3. Hematological and laboratory data
Hematological and laboratory tests showed signiﬁcantly lower va-
lues in white blood cells (WBC), absolute neutrophil count (ANC), he-
moglobin (Hb), platelet (PLT), and ferritin in JPN than CAUC (Table 1).
There was also signiﬁcant diﬀerence in peripheral blood (PB) and bone
marrow (BM) blast percentage between the two groups with less blasts
in both PB and BM for JPN (P= 0.003, and P=0.015, for PB and BM
blast percentage, respectively).
3.4. Cytogenetic data and cytogenetic risk groups
The frequency of IPSS-R cytogenetic groups was compared between
two groups [30]. The distribution in the cytogenetic risk groups (IPSS-R
risk) was not diﬀerent between JPN and CAUC (Table 1, P= 0.332).
The percentage of normal karyotype was 65.3% and 62.7% in JPN
(n=300) and CAUC (n=5838) groups, respectively, without sig-
niﬁcant diﬀerence (P= 0.382). To compare the frequency of each
aberration used in IPSS-R risk stratiﬁcation, data which met ISCN cri-
teria were selected and further analyzed (n=5105) [31]. Among 27
types of cytogenetic aberrations, we found signiﬁcantly higher fre-
quencies of +1/+1q, -1/del(1q), der(1;7), -9/del(9q), del(16q) and del
(20q) in the JPN group (Table 2). Del(5q) was signiﬁcantly lower
among JPN (1.9%, 5 out of 261 cases) than CAUC patients (8.6%, 415
out of 4844 cases) (Table 2, P < 0.001). The diﬀerences in the cyto-
genetic abnormalities did not change in patients younger than 40 years
(data not shown).
3.5. IPSS-R risk group and IPSS-RA score
For the comparison of IPSS-R between JPN and CAUC patients, in-
itially raw IPSS-R scores were compared. The median IPSS-R score for
JPN MDS was 3.5, which was signiﬁcantly higher than that for CAUC
(score= 3.0) (P < 0.001), and this diﬀerence was reﬂected in the
distribution in IPSS-R risk groups (P < 0.001, Table 1). JPN group
contained more Intermediate risk, and less Very Low risk patients. We
next analyzed the score of age-adjusted IPSS-R (IPSS-RA).18 The dif-
ference in IPSS-RA score between JPN (3.35) and CAUC (3.0) became
smaller compared with IPSS-R raw scores, but the signiﬁcant diﬀerence
persisted (P= 0.007). When IPSS-RA was used to categorize MDS pa-
tients, signiﬁcant diﬀerence remained in the distribution of patients
between the two groups (P=0.010, Table 3).
3.6. Overall survival and time to AML evolution
Statistically signiﬁcant diﬀerences in the time to AML transforma-
tion between JPN and CAUC patients were not seen (P=0.625,
Fig. 1B). However, overall survival was signiﬁcantly longer in JPN
compared to CAUC patients (median survival time 67.5 and 41.5
months, respectively, P < 0.001, Fig. 1A). Because age and the dis-
tribution in FAB subtypes were markedly diﬀerent between JPN and
CAUC patients even in the groups aged 40 and older (Table 1), survival
time and time to AML were re-calculated with the adjustment for these
two factors. There was no signiﬁcant diﬀerence in time to AML. How-
ever, survival was still longer in JPN patients (P= 0.005, Fig. 1A).
Survival time after AML transformation was also diﬀerent between two
groups after adjustment for age and FAB: JPN and CAUC patients
showed median survival time of 4.9 and 2.6 months, respectively
(P= 0.009). This ﬁnding is consistent with the signiﬁcant diﬀerences in
overall survival between the two patient groups, given that JPN shows
longer intervals before and after transformation. Survival diﬀerence
remained when younger groups, for example, for patients under age 50
or 60 years, respectively, were considered (data not shown).
3.7. Impact of each factor in IPSS-R score on survival and time to AML, and
application of IPSS-R for JPN MDS
To further analyze the diﬀerences in OS between JPN and CAUC, we
compared OS by IPSS-R risk groups after adjustment for age and FAB
subtypes. The survival diﬀerence between JPN and CAUC remained
signiﬁcant if simultaneously taking into account age, FAB and IPSS-R
categories (P=0.015). As shown in Table 4 and Fig. 2, OS of JPN and
CAUC MDS were subdivided into ﬁve groups and demonstrated sub-
stantially increased OS of JPN patients in Very Low, Low, and Inter-
mediate groups.
The impact of individual prognostic factors in the IPSS-R was
Fig. 1. Comparison of survival (A) and
time to AML transformation (B) be-
tween JPN and CAUC MDS (Kaplan-
Meier curves). Broken green lines re-
presented survival curves of JPN with
raw data. Green lines showed JPN data
with the adjustment for age and FAB
subtypes to those of CAUC. Red lines
were for CAUC. There were signiﬁcant
diﬀerences in survival between two
groups with or without adjustment, al-
though the diﬀerence was smaller after
the adjustment for age and FAB sub-
types. There was no diﬀerence in time
to AML transformation. (For inter-
pretation of the references to colour in
this ﬁgure legend, the reader is referred
to the web version of this article.)
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Table 4
Impact of factors on OS and time to AML transformation.
* 95% conﬁdence interval.
25% AML trans, time to transform AML in 25% of the patients.
NR, not reached.
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evaluated (Table 4). In the comparison between JPN and CAUC, Dxy
values for cytopenias (i.e., levels of Hb, PTL, and ANC) were smaller in
JPN than CAUC, demonstrating smaller prognostic impact on survival
and time to AML transformation. Some P values for Dxy of cytopenia-
related factors showed no signiﬁcant impact among JPN patients. On
the other hand, Dxy of BM blast percentage was larger in JPN for both
OS and time to AML transformation than CAUC. Dxy of cytogenetic risk
group for JPN was larger for OS, but smaller for time to AML than
CAUC. IPSS-R that combined these factors in JPN showed 0.51 for OS
and 0.49 for time to AML, which were comparable to those of CAUC
(0.42 and 0.53 for OS and time to AML, respectively). These data in-
dicated a stronger impact of blast percentage and cytogenetics as
compared to cytopenias on outcomes in the IPSS-R for JPN vs CAUC.
4. Discussion
In this study, by comparing clinical features of JPN and CAUC MDS
patients, we found a striking diﬀerence in OS, but not in time to AML
transformation. The improved survival diﬀerence between JPN and
CAUC remained signiﬁcant even when simultaneously taking into ac-
count age, FAB and IPSS-R categories. The diﬀerence in OS was large,
especially in lower-risk IPSS-R categories Very Low, Low, and
Intermediate risk groups. Several clinical factors were also found sig-
niﬁcantly diﬀerent between the two patient groups. These factors were
age, levels of cytopenias, percentages of PB and BM blasts, serum fer-
ritin, and the frequencies of several karyotypes. Among them, the
median values of ANC and ferritin in JPN centers were smaller than
those of each CAUC center, respectively. Except for one JPN center, the
same was true for hemoglobin and platelets. These ﬁndings indicated
the presence of markedly, signiﬁcant diﬀerence in these factors be-
tween JPN and CAUC. Although there was no signiﬁcant diﬀerence in
the frequency of dysplasia in three lineages (data not shown), the dis-
tributions in FAB and WHO morphologic subtypes also showed diﬀer-
ences. The diﬀerences in classiﬁcations were mainly found in those with
low blast percentages (RA and RARS in FAB, and RARS, RCMD and 5q-
syndrome in WHO classiﬁcations). Signiﬁcantly lower PB and BM blast
percentages in JPN was reﬂected, at least in part, in the diﬀerent per-
centage of RAEB-1 in WHO classiﬁcation (10.6% for JPN, and 17.7% for
CAUC), though those of RAEB-2 were similar (21.2% for JPN, and
18.7% for CAUC).
In our relatively large JPN patient cohort, new diﬀerential features
were identiﬁed between JPN and CAUC, including diﬀering karyotypic
frequencies and diﬀerences in OS. The incidence of +1/+1q, -1/del
(1q), der(1;7), -9/del(9q), del(16q) and del(20q) was signiﬁcantly in-
creased in JPN while Del(5q) was decreased.
The diﬀerence in OS between JPN and CAUC was still observed after
the adjustment for age and FAB subtypes in the two groups, demon-
strating that younger age of JPN patients was not crucial for the sig-
niﬁcant diﬀerence in OS. IPSS-R score (and IPSS-RA score) was higher
in JPN, but OS was longer in JPN. This suggested that the clinical
factors used in IPSS-R had diﬀerent impact on OS in JPN and CAUC.
The analysis demonstrated that Dxy's of cytopenias was smaller, and
those for BM blasts and cytogenetic risk category were higher for OS but
not for AML transformation in JPN than CAUC patients. These ﬁndings
ﬁt the results of OS and AML comparisons in these two patient cohorts.
Importantly, these patients were all untreated by disease-modifying
agents. Thus, the inﬂuence of such treatments on OS would not have
confounded the results. Several explanations exist regarding possible
reasons for the demonstrated survival diﬀerences between JPN and
CAUC: diﬀerences in disease subgroup distribution, patients’ care, en-
vironmental factors including diet, incidence of accompanying diseases
such as cardiovascular diseases or other malignancies, and clinically
relevant ethnic features. The survival diﬀerences between JP and
CAUC, particularly in lower risk categories are concordant with a
comparatively low general mortality in Japan [32].
Some of these diﬀerences were previously found in studies com-
paring MDS of an Asian country and European countries with or
without USA [12–15]. In the report comparing JPN and German RA
[15], the authors showed that JPN patients were younger, and had
more severe cytopenias, less del(5q), and better OS. In our study, we
compared individual MDS subtypes with larger numbers of JPN and a
broader group of CAUC patients, and conﬁrmed and extended the
previous ﬁndings. Other reports from China [12], Thailand [13], and
Korea [14] also reported younger ages of MDS patients, suggesting that
this is a common characteristic of Asian MDS. Recently, a Japanese
group reported clinical features of a group of MDS patients (not in-
cluded in this study) with data from 2006 to 2016, and demonstrated a
median age of 68 years [22], which was older than the age of JPN in our
cohort, albeit still younger than that of CAUC. This may relate to the
rapid aging of recent Japanese society.
In summary, our results indicated that clinically relevant hemato-
logical, cytogenetic, and survival diﬀerences existed between JPN and
CAUC MDS, and that the IPSS-R diﬀerentiates risk groups in JPN as well
as CAUC patients. Detailed genome sequence and mutational analysis
comparison between JPN and CAUC MDS will likely provide further
useful answers to issues underlying such diﬀerences between these
patient cohorts. Although it is in principle impossible to be sure about
the causes of the diﬀerences, such investigations may stimulate clini-
cally promising hypotheses. The potential existence of ethnic diﬀer-
ences could raise concerns about the adequacy of combined analyses,
but the good performance of the IPSS-R in both CAUC and JP patients
underlines that this can successfully be done, as long as ethnically
heterogeneous data is analyzed properly i.e. by stratiﬁcation, as it was
done in the development of the IPSS-R.
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